Clinical Trial Update: Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 given before prostatectomy in prostate cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Prostatic Neoplasms | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING